PHAT
Phathom Pharmaceuticals, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 26 ▲ Phathom Pharmaceuticals reported strong financial results for Q4 and…
- May 20 FDA: Phathom Pharmaceuticals Highlights Breadth of Independent…
- Jun 23 FDA: Phathom Pharmaceuticals Completes Patient Enrollment Ahead…
- Jul 30 ▼ Phathom reported Q2 2026 net revenue of $74.3M, up 88% YoY and above…
- Sep 9 Leerink Partners initiates
- Oct 23 ▼ Phathom disclosed that BDR Pharmaceuticals has sued the FDA challeng…
- Oct 29 ▲ Phathom Pharmaceuticals reported Q3 2026 net revenue of $84.7M, up 7…
- Oct 29 ▲ Earnings: PHAT Q3 2026 Earnings: EPS $0.04 (+128.3% vs est)
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q3 2026: 23 added (0 new), 13 trimmed or exited.
- AnalystsBULLISH
15 of 17 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −5.9% to 9.20M shares. 4.8 days to cover, ≈11.3% of shares.
- TrendDOWNTREND
15% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| WASATCH ADVISORS LP | DOUBLED | $21.5M |
| STATE STREET CORP | ADD | $14.6M |
| UBS Group AG | ADD | $2.7M |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $1.4M |
| Squarepoint Ops LLC | DOUBLED | $1.0M |
| MORGAN STANLEY | TRIM | $784.4K |
| BARCLAYS PLC | DOUBLED | $781.8K |
| CITIGROUP INC | ADD | $629.8K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
17 analystsPrice is below the lowest target. Median implies +266%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 9, 2026 | Leerink Partners INITIATE | Market Perform |
| Aug 17, 2026 | Barclays MAINTAIN | Overweight |
| Jul 31, 2026 | Guggenheim MAINTAIN | Buy |
| Jul 31, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Jul 30, 2026 | Needham MAINTAIN | Buy |
| Jun 17, 2026 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Narula Sanjeev Chief Financial & Bus. Officer Oct 6, 2026 | TAX W/H | $91.4K |
Breedlove Robert Charles Principal Accounting Officer Sep 3, 2026 | TAX W/H | $4.2K |
Breedlove Robert Charles Principal Accounting Officer Jul 14, 2026 | TAX W/H | $17.2K |
Parikh Asit Director May 22, 2026 | GIFT | 28,000 sh |
Parikh Asit Director May 20, 2026 | EXERCISE | $86.6K |
Parikh Asit Director May 20, 2026 | TO ISSUER | 17,500 sh |
Parikh Asit Director May 19, 2026 | AWARD | 24,122 sh |
KARBE FRANK Director May 19, 2026 | AWARD | 24,122 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | $0.02 | -$0.03–$0.07 | -73.9% | $94.0M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
14 filings · 2 press releases · 3 bullish · 3 bearish · 2 mixed · 6 neutral- NEUTRAL SC 13G/ANov 10, 2026
Invesco Ltd. filed an amendment to its Schedule 13G for Phathom Pharmaceuticals, reporting…
Invesco's stake is negligible and unchanged in any material way. No action warranted; the filing is routine.
- NEUTRAL SC 13D/ANov 2, 2026
Frazier Life Sciences filed Amendment No. 12 to its Schedule 13D for Phathom Pharmaceuticals…
Monitor for any future amendments that disclose a change in purpose or new activist demands; the current filing is purely administrative and does not alter the investment thesis.
- BULLISH 8-KOct 29, 2026
Phathom Pharmaceuticals reported Q3 2026 net revenue of $84.7M, up 71% YoY and 14% sequentially…
Revenue growth of 71% YoY and the achievement of non-GAAP adjusted net income demonstrate accelerating commercial execution. The key catalyst to watch is the Phase 2 EoE topline readout expected in…
- BULLISH PRESS-RELEASEOct 29, 2026
Phathom Pharmaceuticals reported Q3 2026 net revenue of $84.7M, up 71% YoY and above the $84.8M…
Revenue growth and cash flow positivity are encouraging, but the company remains GAAP net loss-making. Watch for topline results from the Phase 2 EoE trial (pHalcon-EoE-201) expected in Q4 2026 and…
All PHAT filing & press-release reports (16)
- SC 13G/A reportNov 10, 2026
- SC 13D/A reportNov 2, 2026
- 8-K reportOct 29, 2026
- PRESS-RELEASE reportOct 29, 2026
- 8-K reportOct 26, 2026
- 8-K reportOct 23, 2026
- PRESS-RELEASE reportOct 19, 2026
- 8-K reportSep 29, 2026
- 8-K reportJul 30, 2026
- PRESS-RELEASE reportJul 30, 2026
- PRESS-RELEASE reportJul 20, 2026
- PRESS-RELEASE reportMay 20, 2026
- PRESS-RELEASE reportMay 1, 2026
- PRESS-RELEASE reportApr 30, 2026
- DEFA14A reportApr 7, 2026
- 8-K reportFeb 26, 2026